VARIABLE BIOAVAILABILITY OF ORAL MERCAPTOPURINE - IS MAINTENANCE CHEMOTHERAPY IN ACUTE LYMPHOBLASTIC-LEUKEMIA BEING OPTIMALLY DELIVERED

被引：252

作者：

ZIMM, S

COLLINS, JM

RICCARDI, R

ONEILL, D

NARANG, PK

CHABNER, B

POPLACK, DG

机构：

[1] NCI,DIV CANC TREATMENT,PEDIAT BRANCH,LEUKEMIA BIOL SECT,BLDG 10,ROOM 13N240,BETHESDA,MD 20205

[2] NIH,DIV RES SERV,BIOMED ENGN & INSTRUMENTAT BRANCH,BETHESDA,MD 20205

[3] NIH,CTR CLIN,DEPT PHARM,PHARMACEUT DEV SERV,BETHESDA,MD 20205

来源：

关键词：

D O I：

10.1056/NEJM198304283081705

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1005 / 1009

页数：5

共 26 条

[1] NONCOMPARTMENTAL DETERMINATION OF THE STEADY-STATE VOLUME OF DISTRIBUTION
BENET, LZ
GALEAZZI, RL
[J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (08) : 1071 - 1074
[2] BROCKMAN RW, 1963, CANCER RES, V23, P1191
[3] CLINICAL EVALUATION OF A NEW ANTIMETABOLITE, 6-MERCAPTOPURINE, IN THE TREATMENT OF LEUKEMIA AND ALLIED DISEASES
BURCHENAL, JH
MURPHY, ML
ELLISON, RR
SYKES, MP
TAN, TC
LEONE, LA
KARNOFSKY, DA
CRAVER, LF
DARGEON, HW
RHOADS, CP
[J]. BLOOD, 1953, 8 (11) : 965 - 999
[4] DING TL, 1979, DRUG METAB DISPOS, V7, P373
[5] SIGNIFICANCE OF AZATHIOPRINE METABOLITES
ELION, GB
[J]. PROCEEDINGS OF THE ROYAL SOCIETY OF MEDICINE-LONDON, 1972, 65 (03): : 257 - +
[6] ELION GB, 1967, FED PROC, V26, P898
[7] ERLICHMAN C, 1980, CANCER CHEMOTH PHARM, V4, P139
[8] FREIREICH EJ, 1963, BLOOD, V21, P699
[9] Gibaldi M, 1975, PHARMACOKINETICS, P281
[10] HORAKOVA K, 1974, BIOCH BIOPHYS ACTA, V336, P333